Human Growth Hormone Industry Overview
The global human growth hormone market size was valued at USD 4.6 billion in 2019 and is estimated to register a CAGR of 8.2% over the forecast period.
Factors such as investments by market players, the presence of a strong pipeline, extensive R&D activities, robust product portfolio, and increasing government initiatives are expected to significantly drive the market. Human growth hormone (HGH), also known as somatotropin, is a peptide hormone responsible for growth stimulation, cell reproduction, and cell regeneration in humans and is hence important for human development. Growth hormone (GH) deficiency in humans is caused when the pituitary gland does not synthesize enough concentration of hGH. This deficiency in humans is treated by administering recombinant human growth hormone by subcutaneous injection. Various genetic disorders, including Prader-Willi syndrome and Turner syndrome, may also cause growth hormone deficiency in humans, leading to delayed puberty and shorter-than-average height.
Gather more insights about the market drivers, restrains and growth of the Global Human Growth Hormone Market
According to data published by the American Academy of Pediatrics, growth hormone deficiency among humans is a rare condition and affects less than one in 3,000 to one in 10,000 children in U.S. Currently, hGH is widely abused as an anti-aging treatment in older adults and as a performance-enhancing anabolic drug by bodybuilders and athletes. However, HGH is a controlled substance as per the USFDA and has not been approved for anti-aging and performance-enhancing indications.
Robust product pipeline and extensive R&D activities for the development of novel growth hormone therapies are expected to be the major factors driving the market for human growth hormones. For instance, in September 2018, Novo Nordisk presented Phase II clinical trial data of its investigational GH therapy, Somapacitan, indicated for the treatment of pediatric growth hormone deficiency. In addition, in May 2019, Ascendis Pharma A/S published results from the Phase III clinical trial of its TransCon hGH, indicated for pediatric growth hormone deficiency. Similarly, various key players including Teva Pharmaceutical Industries, Ltd.; OPKO Health, Inc.; Eli Lilly and Company; Ferring Pharmaceuticals; Sanofi S.A.; and LG Life Sciences are involved in R&D activities for the development of novel human growth hormone therapies.
Furthermore, initiatives taken by various government and private organizations to spread awareness about GH deficiencies and human growth hormone treatment are expected to drive the market. Every year, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), a U.S.-based nonprofit charitable organization, celebrates International Children’s Growth Awareness Day to spread awareness about the early diagnosis and treatment of growth hormone disorders among humans, especially children.
However, the high cost of hGH therapies and various adverse effects related to hGH may hinder market progress over the forecast period. For instance, according to UPMC Children’s Hospital of Pittsburgh, the possible side effects of GH hormone therapy include knee, hip, or other joint pain; allergic reactions, including rash, swelling, or hives; and an increase in blood sugar levels.
Browse through Grand View Research's Pharmaceuticals Industry Research Reports.
- Active Pharmaceutical Ingredients Market – The global active pharmaceutical ingredients market size was valued at USD 209.7 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.0% from 2022 to 2030.
- Antifungal Drugs Market – The global antifungal drugs market size was valued at USD 14.8 billion in 2021 and is projected to witness a compound annual growth rate (CAGR) of 3.7% from 2022 to 2030. The growing prevalence of fungal infections such as aspergillosis and candidiasis is one of the key factors propelling the market.
Human Growth Hormone Market Segmentation
Grand View Research has segmented the global human growth hormone market on the basis of application, distribution channel, and region:
Human Growth Hormone (HGH) Application Outlook (Revenue, USD Million, 2016 – 2027)
- Growth Hormone (GH) Deficiency
- Adult GH Deficiency
- Pediatric GH Deficiency
- Turner Syndrome
- Idiopathic Short Stature
- Prader-Willi Syndrome
- Small for Gestational Age
Human Growth Hormone (HGH) Distribution Channel Outlook (Revenue, USD Million, 2016 – 2027)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Specialty Pharmacy
Human Growth Hormone (HGH) Regional Outlook (Revenue, USD Million, 2016 – 2027)
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Market Share Insights
- October 2018: Novo Nordisk and Strongbridge Biopharma signed an agreement to acquire the rights to MACRILEN in the U.S. and Canada.
- March 2017: Novo Nordisk A/S, a Denmark-based pharmaceutical company, initiated the phase III clinical trial of its HGH somapacitan, indicated for the treatment of adult growth hormone deficiency, in Japan.
Key Companies profiled:
Some prominent players in the global human growth hormone market include
- Novo Nordisk A/S
- Eli Lilly and Company
- Sandoz International GmbH (Novartis AG)
- Merck KGaA
- Genentech, Inc (Roche)
- Ferring Pharmaceuticals
- Teva Pharmaceutical Industries, Ltd
Order a free sample PDF of the Human Growth Hormone Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Corporate Sales Specialist, USA
Grand View Research, Inc.
Toll Free: 1-888-202-9519